Gracell Biotechnologies Inc ADR [GRCL] stock is trading at $4.94, up 5.11%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GRCL shares have gain 12.27% over the last week, with a monthly amount glided 78.99%, and seem to be holding up well over a long-time horizon.
On 16, November 2023, Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit. In a post published today on Yahoo Finance, Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease.
From an analyst’s perspective:
Gracell Biotechnologies Inc ADR [NASDAQ: GRCL] stock has seen the most recent analyst activity on October 19, 2023, when Stifel initiated its Buy rating and assigned the stock a price target of $11.
Gracell Biotechnologies Inc ADR [GRCL] stock has fluctuated between $1.40 and $6.99 over the past year. Currently, Wall Street analysts expect the stock to reach $11.71 within the next 12 months. Gracell Biotechnologies Inc ADR [NASDAQ: GRCL] shares were valued at $4.94 at the most recent close of the market. An investor can expect a potential return of 137.04% based on the average GRCL price forecast.
Analyzing the GRCL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -32.14, Equity is -37.23, Total Capital is -34.66, and Invested Capital is -35.87. Taking a look at the Principal structure of this organization reveals enduring liabilities to the total capital at 11.74 and enduring liabilities to the whole assets at 11.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.73 points at the first support level, and at 4.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.07, and for the 2nd resistance point, it is at 5.20.
Gracell Biotechnologies Inc ADR [GRCL] reported earnings per share of -$0.1 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.2/share, meaning a difference of $0.1 and a surprise factor of 50.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.3 per share as compared to estimates of -$0.4 per share, a difference of $0.1 representing a surprise of 25.00%.
Ratios To Look Out For
For context, Gracell Biotechnologies Inc ADR’s Current Ratio is 7.73. In addition, the Quick Ratio stands at 6.78 and the Cash Ratio stands at 6.61.